These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31523950)

  • 41. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity.
    Chatenoud L
    Curr Opin Organ Transplant; 2009 Aug; 14(4):351-6. PubMed ID: 19610168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.
    Thakkar S; Chopra A; Nagendra L; Kalra S; Bhattacharya S
    touchREV Endocrinol; 2023 Nov; 19(2):22-30. PubMed ID: 38187075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.
    Sims EK; Cuthbertson D; Jacobsen L; Ismail HM; Nathan BM; Herold KC; Redondo MJ; Sosenko J
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2116-2123. PubMed ID: 38267821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
    Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
    Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice.
    Sarikonda G; Sachithanantham S; Miller JF; Pagni PP; Coppieters KT; von Herrath M
    J Autoimmun; 2015 May; 59():61-6. PubMed ID: 25772283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention strategies for type 1 diabetes mellitus: current status and future directions.
    Winter WE; Schatz D
    BioDrugs; 2003; 17(1):39-64. PubMed ID: 12534319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-CD3 mAbs for treatment of type 1 diabetes.
    Kaufman A; Herold KC
    Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention and reversal of type 1 diabetes--past challenges and future opportunities.
    Skyler JS
    Diabetes Care; 2015 Jun; 38(6):997-1007. PubMed ID: 25998292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D.
    Linsley PS; Long SA
    Curr Opin Endocrinol Diabetes Obes; 2019 Aug; 26(4):213-218. PubMed ID: 31157632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Testing agents for prevention or reversal of type 1 diabetes in rodents.
    Grant CW; Moran-Paul CM; Duclos SK; Guberski DL; Arreaza-Rubín G; Spain LM
    PLoS One; 2013; 8(8):e72989. PubMed ID: 24023664
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.
    Maurice Morillon Y; Martin A; Gojanovich G; Wang B; Tisch R
    Arch Immunol Ther Exp (Warsz); 2015 Aug; 63(4):239-50. PubMed ID: 25790749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine therapies for the prevention of type 1 diabetes mellitus.
    Petrovsky N; Silva D; Schatz DA
    Paediatr Drugs; 2003; 5(9):575-82. PubMed ID: 12956615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation.
    Valle A; Barbagiovanni G; Jofra T; Stabilini A; Perol L; Baeyens A; Anand S; Cagnard N; Gagliani N; Piaggio E; Battaglia M
    J Immunol; 2015 Mar; 194(5):2117-27. PubMed ID: 25646305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
    Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
    Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Monoclonal antibodies in diabetes: almost approaching the dream?].
    Philips JC; Keymeulen B; Mathieu C; Scheen AJ
    Rev Med Liege; 2009; 64(5-6):327-33. PubMed ID: 19642469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-antigenic and antigenic interventions in type 1 diabetes.
    Rydén AK; Wesley JD; Coppieters KT; Von Herrath MG
    Hum Vaccin Immunother; 2014; 10(4):838-46. PubMed ID: 24165565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Journey of Teplizumab: A Promising Drug in the Treatment of Type 1 Diabetes Mellitus.
    Sharma N; Das DD; Chawla PA
    Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38279734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
    Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK
    Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.
    Glandt M; Herold KC
    Curr Diab Rep; 2004 Aug; 4(4):291-7. PubMed ID: 15265472
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Teplizumab: type 1 diabetes mellitus preventable?
    Misra S; Shukla AK
    Eur J Clin Pharmacol; 2023 May; 79(5):609-616. PubMed ID: 37004543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.